Skip to main content
. 2021 Jul 4;8(3):1241–1253. doi: 10.1007/s40744-021-00335-7
Anakinra is prescribed for cases of refractory crystal-associated arthritis or contraindications to usual treatments
The efficacy of anakinra in treating calcium pyrophosphate crystal deposition disease is not obvious
Anakinra is the most prescribed therapeutic, and its efficiency in treating gout was high
Anti-IL-1 therapies are generally introduced with a long-term objective